MARKSANS.BO
Marksans Pharma Limited
BSEINREQUITY
Healthcare
DELAYED
Last price
324.00
▲ 2.75 (0.86%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
322.60
Prev close
321.25
Day high
325.40
Day low
317.85
Volume
148.50K
Market cap
$146.94B
P/E (TTM)
41.75
52W range
157.25 – 325.40
Day trading desk
Gap from prior close
—
—
VWAP
322.35
+0.51% from price
Relative volume
5.55×
Unusually busy
Session range
2.38%
317.85 – 325.40
Position in range
81%
Near session high
ATR (14D)
—
Daily true range
Prior day high
—
PDH
Prior day low
—
PDL
Bid / ask spread
—
Quote not published
Session volume
292.57K
Avg 52.68K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MARKSANS.BO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
198.65M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 11, 25 | Orbimed Asia Mauritius Ltd Institution- Corporation |
— | 10.27M | — | Direct |
| Jun 5, 24 | Saldanha (Sandra) Promoter |
BUY | 63.28K | $107.38K | Direct |
| Jun 3, 24 | Saldanha (Sandra) Promoter |
BUY | 47.00K | $82.59K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Orbimed Asia Mauritius Ltd |
Institution- Corporation | 39.05M | Sale |
Saldanha (Sandra) |
Promoter | 330.46K | Acquisition |
Fundamentals
Market cap$146.94B
Enterprise value$78.20B
Revenue (TTM)$27.31B
Gross profit$14.82B
EBITDA$4.71B
Net income$3.52B
EPS (TTM)$7.76
Free cash flow$-1.28B
Total cash$6.67B
Total debt$3.32B
Book value / share$59.37
Shares outstanding453.16M
Float214.28M
Short % of float—
Dividend yield0.45%
Beta (5Y)1.07
Valuation & profitability ratios
Trailing P/E41.75
Forward P/E31.35
PEG ratio—
Price / sales—
Price / book5.46
EV / revenue2.86
EV / EBITDA16.62
Gross margin54.29%
Operating margin16.32%
Profit margin12.88%
Return on equity14.07%
Return on assets7.96%
Debt / equity12.24
Current ratio5.18
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $29.42B | $26.14B | $21.74B | $18.50B | +12.5% |
| Operating revenue | $29.42B | $26.14B | $21.74B | $18.50B | +12.5% |
| Cost of revenue | $13.73B | $12.29B | $10.97B | $9.58B | +11.6% |
| Gross profit | $15.69B | $13.85B | $10.77B | $8.92B | +13.3% |
| Selling, general & admin | $2.87B | $2.81B | $1.45B | $1.50B | +2.2% |
| Total operating expense | $10.54B | $9.29B | $6.90B | $5.79B | +13.4% |
| Operating income | $5.15B | $4.56B | $3.87B | $3.13B | +13.1% |
| Net interest income | $35.53M | $185.37M | $225.84M | $29.09M | -80.8% |
| Pre-tax income | $5.61B | $5.04B | $4.24B | $3.38B | +11.2% |
| Tax provision | $1.40B | $1.21B | $1.09B | $723.32M | +15.8% |
| Net income | $4.18B | $3.81B | $3.14B | $2.66B | +9.8% |
| Net income to common | $4.18B | $3.81B | $3.14B | $2.66B | +9.8% |
| EBIT | $5.85B | $5.16B | $4.35B | $3.43B | +13.4% |
| EBITDA | $6.83B | $5.99B | $5.09B | $3.95B | +14.1% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.34B | $4.96B | $4.03B | $3.82B | — | +27.9% |
| Cash & short-term investments | $9.89B | $7.05B | $7.00B | $7.15B | — | +40.4% |
| Accounts receivable | $6.45B | $5.40B | $4.53B | $4.17B | — | +19.4% |
| Inventory | $9.72B | $8.46B | $6.18B | $4.85B | — | +15.0% |
| Total current assets | $27.23B | $22.04B | $18.62B | $16.75B | — | +23.5% |
| Property, plant & equipment | $9.41B | $9.00B | $6.93B | $3.93B | — | +4.6% |
| Goodwill & intangibles | $1.62B | $1.14B | $1.04B | $1.09B | — | +42.6% |
| Total assets | $38.61B | $32.40B | $26.81B | $21.90B | — | +19.2% |
| Total current liabilities | $5.27B | $4.77B | $3.90B | $3.41B | — | +10.4% |
| Current debt | $295.91M | $230.85M | $290.91M | $415.88M | — | +28.2% |
| Long-term debt | — | — | — | — | $0 | — |
| Total debt | $3.43B | $3.22B | $2.44B | $1.23B | — | +6.7% |
| Total liabilities | $8.08B | $7.50B | $5.95B | $4.25B | — | +7.7% |
| Retained earnings | $18.05B | $14.22B | $10.69B | $7.78B | — | +26.9% |
| Shareholder equity | $30.23B | $24.67B | $20.65B | $17.45B | — | +22.5% |
| Working capital | $21.96B | $17.27B | $14.73B | $13.34B | — | +27.2% |
| Net tangible assets | $28.61B | $23.53B | $19.61B | $16.36B | — | +21.6% |
| Shares issued | 453.16M | 453.16M | 453.16M | 453.16M | — | 0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Net income | $5.61B | $5.04B | $4.24B | $3.38B | — | +11.2% |
| Depreciation & amortisation | $986.32M | $833.86M | $742.70M | $518.53M | — | +18.3% |
| Stock-based compensation | $33.38M | $0 | — | — | — | — |
| Change in working capital | -$624.57M | -$2.41B | -$1.26B | -$1.11B | — | +74.1% |
| Operating cash flow | $4.58B | $2.07B | $2.30B | $2.37B | — | +121.7% |
| Capital expenditure | -$1.31B | -$1.73B | -$2.09B | -$536.31M | — | +24.5% |
| Investing cash flow | -$2.48B | -$490.09M | -$1.41B | -$2.59B | — | -406.6% |
| Share buybacks | — | — | $0 | -$451.66M | $0 | — |
| Dividends paid | -$362.53M | -$271.90M | -$226.58M | -$101.71M | — | -33.3% |
| Financing cash flow | -$709.28M | -$651.46M | -$687.27M | $1.98B | — | -8.9% |
| Free cash flow | $3.28B | $337.45M | $215.69M | $1.84B | — | +870.8% |
| End cash position | $6.34B | $4.96B | $4.03B | $3.82B | — | +27.9% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $8.56B | $7.54B | $7.20B | $6.20B | $7.08B | +13.5% |
| Operating revenue | $8.56B | $7.54B | $7.20B | $6.20B | $7.08B | +13.5% |
| Cost of revenue | $3.91B | $3.16B | $3.09B | $2.62B | $3.25B | +23.5% |
| Gross profit | $4.65B | $4.38B | $4.12B | $3.58B | $3.83B | +6.2% |
| Total operating expense | $2.94B | $3.02B | $2.94B | $2.81B | $2.79B | -2.5% |
| Operating income | $1.71B | $1.36B | $1.18B | $770.22M | $1.04B | +25.5% |
| Net interest income | -$63.10M | -$59.35M | -$58.15M | -$60.65M | -$34.35M | -6.3% |
| Pre-tax income | $2.00B | $1.51B | $1.33B | $765.98M | $1.16B | +32.8% |
| Tax provision | $509.66M | $369.34M | $341.95M | $183.96M | $253.68M | +38.0% |
| Net income | $1.48B | $1.13B | $982.50M | $583.17M | $905.46M | +30.9% |
| Net income to common | $1.48B | $1.13B | $982.50M | $583.17M | $905.46M | +30.9% |
| EBIT | $2.06B | $1.57B | $1.39B | $826.63M | $1.20B | +31.8% |
| EBITDA | $2.31B | $1.81B | $1.66B | $1.06B | $1.42B | +27.5% |
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $6.34B | $4.82B | $4.96B | +31.7% |
| Cash & short-term investments | $9.89B | $6.71B | $7.05B | +47.4% |
| Accounts receivable | $6.45B | $6.03B | $5.40B | +6.9% |
| Inventory | $9.72B | $9.55B | $8.46B | +1.8% |
| Total current assets | $27.23B | $23.54B | $22.04B | +15.7% |
| Property, plant & equipment | $9.41B | $9.23B | $9.00B | +2.0% |
| Goodwill & intangibles | $1.62B | $1.38B | $1.14B | +17.8% |
| Total assets | $38.61B | $34.42B | $32.40B | +12.2% |
| Total current liabilities | $5.27B | $4.55B | $4.77B | +15.9% |
| Current debt | $295.91M | $233.75M | $230.85M | +26.6% |
| Total debt | $3.43B | $3.32B | $3.22B | +3.4% |
| Total liabilities | $8.08B | $7.28B | $7.50B | +11.0% |
| Retained earnings | $18.05B | — | $14.22B | — |
| Shareholder equity | $30.23B | $26.88B | $24.67B | +12.5% |
| Working capital | $21.96B | $19.00B | $17.27B | +15.6% |
| Net tangible assets | $28.61B | $25.50B | $23.53B | +12.2% |
| Shares issued | 453.16M | 453.16M | 453.16M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2025 | 2.40 | 2.50 | +4.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | 8.67 | 3 | $28.11B | +7.2% |
| Next year | 10.33 | 3 | $32.05B | +14.0% |
Analyst targets & ownership
Mean target$225.33
High target$246.00
Low target$210.00
Implied upside-30.45%
Analyst count3
ConsensusNONE
Strong buy / Buy1 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders43.87%
Held by institutions17.95%
Institutions holding27
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
—
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
—
Peak to trough
Max drawdown 5Y
—
Peak to trough
ATR 14
—
Average true range
Beta (reported)
1.07
5Y monthly, from filing
Dividends & splits
Forward rate$0.80 / yr
Forward yield0.45%
5-year avg yield0.33%
Payout ratio10.31%
Ex-dividend dateAug 1, 2025
Next pay date—
Last split10:1
Split dateMar 11, 2008
Headlines
Coca-Cola's stock buybacks: What its latest program means for investors
TheStreet · 2m ago
48-year-old casual dining chain closed 106 locations
TheStreet · 7m ago
Shares dip with pressure from technology, yields and oil fall
Reuters · 8m ago
Samsung Just Authorized Its Largest Shareholder Return Ever. Every Major Memory Stock Fell Monday.
Motley Fool · 10m ago
Aggreko Announces Filing of Registration Statement for Proposed Initial Public Offering
Business Wire · 11m ago
Nashville hospital admits 4 patients got the wrong drug — 1 was left paralyzed. State caps its payouts at $1M
Moneywise · 11m ago
La Rosa Holdings Corp. Announces Receipt of Nasdaq Deficiency Notice and Subsequent Regaining of Compliance
GlobeNewswire · 11m ago
SBA, Department of Energy Partner to Advance President Trump's American Energy Dominance Agenda
PR Newswire · 12m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.